中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 9
Sep.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(9): 1818-1828

Comparative analysis of the predictive value of fried frailty phenotype， liver fraily index and short physical performance battery in the prognosis of patients with liver cirrhosis

DOI: 10.12449/JCH250917
  • 1.

    Department of Geriatrics，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China

  • 2.

    Liver Research Center，State Key Laboratory of Digestive Health，National Clinical Research Center for Digestive Diseases，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China

Research funding:

National Natural Science Foundation of China (82270603)

More Information
  • Corresponding author: JIA Jidong， jia_jd@ccmu.edu.cn （ORCID： 0000-0002-4673-8890）
  • Received Date: 2025-03-18
  • Accepted Date: 2025-05-06
  • Published Date: 2025-09-25
    Abstract
  •   Objective  To investigate the value of Fried Frailty Phenotype （FFP）， liver frailty index （LFI）， and Short Physical Performance Battery （SPPB） in predicting 2-year all-cause mortality and decompensation events in patients with liver cirrhosis.  Methods  A total of 277 patients with liver cirrhosis who were hospitalized in Beijing Friendship Hospital， Capital Medical University， from December 2020 to December 2021 were enrolled， and FFP， LFI， and SPPB were used to assess the state of frailty. Based on the scores of each tool， these patients were divided into frail and non-frail groups. These three tools were compared in terms of consistency and independent predictive performance. The primary endpoints were 2-year all-cause mortality rate and composite endpoints （death+decompensation events）， and the Cox regression analysis， the receiver operating characteristic （ROC） curve， net reclassification index （NRI）， and integrated discrimination improvement （IDI） index were used to analyze the predictive value of the three tools. Normally distributed continuous data were compared between two groups using the independent samples t-test， while non-normally distributed continuous data were compared using the Mann-Whitney U test. Categorical data were compared between groups using the chi-square test or Fisher’s exact test. The agreement among different frailty tools was evaluated using Cohen’s Kappa statistic. The Kaplan-Meier survival curve was plotted， and a survival analysis was performed using the log-rank test.  Results  The prevalence rate of frailty assessed by FFP， LFI， and SPPB was 37.2%， 22.4%， and 20.2%， respectively， with a moderate consistency between FFP and LFI/SPPB （κ=0.57， 95% confidence interval ［CI］： 0.47 — 0.67； κ=0.51， 95%CI： 0.41 — 0.62） and a relatively high consistency between LFI and SPPB （κ=0.87， 95%CI： 0.80 — 0.94）. Compared with the non-frailty group， the frailty group had significantly higher all-cause mortality rate and incidence rate of composite endpoints （P<0.001）. After multivariate adjustment， FFP， LFI， and SPPB had a hazard ratio of 2.42（95%CI： 1.51 — 5.11）， 2.21（95%CI： 1.11 — 4.42）， and 2.21（95%CI： 1.14 — 4.30）， respectively， in predicting all-cause mortality， as well as a hazard ratio of 2.51（95%CI： 1.61 — 3.91）， 2.40（95%CI： 1.51 — 3.80）， and 2.20（95%CI： 1.39 — 3.47）， respectively， in predicting composite endpoints. Compared with Child-Pugh score， FFP had a significantly greater area under the ROC curve （AUC） in predicting all-cause mortality （0.79 vs 0.69， P=0.032） and composite endpoints （0.75 vs 0.68， P=0.044）. Frailty assessment tools combined with Child-Pugh score significantly improved the performance in predicting all-cause mortality and composite endpoints， with an AUC of 0.81 — 0.82 and 0.77 — 0.78， respectively （P<0.05）. NRI and IDI analyses further confirmed the improvement of the combined model in classification （all P<0.001）.  Conclusion  FFP， LFI， and SPPB can independently predict adverse outcomes in patients with liver cirrhosis， among which FFP has the best predictive performance， and the combination of frailty assessment tools with Child-Pugh score can significantly enhance the accuracy of prognostic evaluation.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    TANDON P, MONTANO-LOZA AJ, LAI JC, et al. Sarcopenia and frailty in decompensated cirrhosis[J]. J Hepatol, 2021, 75( Suppl 1): S147- S162. DOI: 10.1016/j.jhep.2021.01.025.
    [2]
    BUNCHORNTAVAKUL C. Sarcopenia and frailty in cirrhosis: Assessment and management[J]. Med Clin North Am, 2023, 107( 3): 589- 604. DOI: 10.1016/j.mcna.2022.12.007.
    [3]
    WANG S, WHITLOCK R, XU C, et al. Frailty is associated with increased risk of cirrhosis disease progression and death[J]. Hepatology, 2022, 75( 3): 600- 609. DOI: 10.1002/hep.32157.
    [4]
    LAI JC, TANDON P, BERNAL W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2021, 74( 3): 1611- 1644. DOI: 10.1002/hep.32049.
    [5]
    SERPER M, TAO SY, KENT DS, et al. Inpatient frailty assessment is feasible and predicts nonhome discharge and mortality in decompensated cirrhosis[J]. Liver Transpl, 2021, 27( 12): 1711- 1722. DOI: 10.1002/lt.26100.
    [6]
    SCHLEICHER EM, KREMER WM, KALAMPOKA V, et al. Frailty as tested by the clinical frailty scale is a risk factor for hepatorenal syndrome in patients with liver cirrhosis[J]. Clin Transl Gastroenterol, 2022, 13( 7): e00512. DOI: 10.14309/ctg.0000000000000512.
    [7]
    Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol, 2019, 35( 6): 1222- 1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.

    中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 临床肝胆病杂志, 2019, 35( 6): 1222- 1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.
    [8]
    LAI JC, SONNENDAY CJ, TAPPER EB, et al. Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice[J]. Am J Transplant, 2019, 19( 7): 1896- 1906. DOI: 10.1111/ajt.15392.
    [9]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [10]
    FRIED LP, TANGEN CM, WALSTON J, et al. Frailty in older adults: Evidence for a phenotype[J]. J Gerontol A Biol Sci Med Sci, 2001, 56( 3): M146- M156. DOI: 10.1093/gerona/56.3.m146.
    [11]
    LAI JC, COVINSKY KE, DODGE JL, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease[J]. Hepatology, 2017, 66( 2): 564- 574. DOI: 10.1002/hep.29219.
    [12]
    PRITCHARD JM, KENNEDY CC, KARAMPATOS S, et al. Measuring frailty in clinical practice: A comparison of physical frailty assessment methods in a geriatric out-patient clinic[J]. BMC Geriatr, 2017, 17( 1): 264. DOI: 10.1186/s12877-017-0623-0.
    [13]
    LAI JC, RAHIMI RS, VERNA EC, et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study[J]. Gastroenterology, 2019, 156( 6): 1675- 1682. DOI: 10.1053/j.gastro.2019.01.028.
    [14]
    CRON DC, FRIEDMAN JF, WINDER GS, et al. Depression and frailty in patients with end-stage liver disease referred for transplant evaluation[J]. Am J Transplant, 2016, 16( 6): 1805- 1811. DOI: 10.1111/ajt.13639.
    [15]
    DENG LX, BISCHOFF KE, KENT DS, et al. Frailty is strongly associated with self-reported symptom burden among patients with cirrhosis[J]. Eur J Gastroenterol Hepatol, 2021, 33( 1 S Suppl 1): e395- e400. DOI: 10.1097/MEG.0000000000002113.
    [16]
    TANDON P, TANGRI N, THOMAS L, et al. A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: A prospective evaluation of the clinical frailty scale[J]. Am J Gastroenterol, 2016, 111( 12): 1759- 1767. DOI: 10.1038/ajg.2016.303.
    [17]
    LAI JC, FENG S, TERRAULT NA, et al. Frailty predicts waitlist mortality in liver transplant candidates[J]. Am J Transplant, 2014, 14( 8): 1870- 1879. DOI: 10.1111/ajt.12762.
    [18]
    SIRAMOLPIWAT S, KIATTIKUNRAT K, SOONTARARATPONG R, et al. Frailty as tested by the Liver Frailty Index is associated with decompensation and unplanned hospitalization in patients with compensated cirrhosis[J]. Scand J Gastroenterol, 2021, 56( 10): 1210- 1219. DOI: 10.1080/00365521.2021.1957497.
    [19]
    ZHAO YF, ZHENG MY, ZHU LH, et al. Research progress on the correlation between cirrhosis and frailty[J]. China J Hepatol, 2023, 31( 8): 891- 896. DOI: 10.3760/cma.j.cn501113-20221229-00614.

    赵娅芳, 郑梦瑶, 朱会灵, 等. 肝硬化与衰弱的相关性研究进展[J]. 中华肝脏病杂志, 2023, 31( 8): 891- 896. DOI: 10.3760/cma.j.cn501113-20221229-00614.
    [20]
    LAI JC, SHUI AM, DUARTE-ROJO A, et al. Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation(FrAILT) Study[J]. Hepatology, 2022, 75( 6): 1471- 1479. DOI: 10.1002/hep.32268.
    [21]
    TAPPER EB, KONERMAN M, MURPHY S, et al. Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index[J]. Am J Transplant, 2018, 18( 10): 2566- 2570. DOI: 10.1111/ajt.15020.
    [22]
    SINGH S, TANEJA S, TANDON P, et al. A comparison of different frailty scores and impact of frailty on outcome in patients with cirrhosis[J]. J Clin Exp Hepatol, 2022, 12( 2): 398- 408. DOI: 10.1016/j.jceh.2021.07.003.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (157) PDF downloads(29) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return